Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's 40th Annual Meeting
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's 40th Annual Meeting
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
Providence Gold Reports Up to 8.0 g/t Au from Mojave Girl Phase 2 Evaluation of Tarantula Gold Mine Set to Begin
Metals Australia Limited Announces Participation in THE Mining Investment Event, Quebec City, June 2-4, 2026
